Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study.

Calabrò L; Caruso FP; Covre A; Noviello TMR; Lofiego MF; Tufano R; Ferraro L; Grisolia P; De Falco A; Lagano V; Sgambelluri F; Sabella G; Rossi G; Gibilisco G; Marzani F; Bello E; Simonetti E; D'Alonzo V; Caraglia M; Coral S; De Angelis A; Cerbone L; Delfanti S; Giannarelli D; Grosso F; Di Giacomo AM; Milione M; Mortarini R; Anichini A; Ceccarelli M; Maio M

doi:10.1038/s41588-026-02580-4

← 뒤로

Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study.

1/5 보강

Nature genetics 2026

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문

P · Population 대상 환자/모집단

91 patients with PM treated in earlier clinical trials or in daily practice identified four PM subsets with progressively increasing global DNA methylation profiles-demethylated, LOW, intermediate and CpG island methylator phenotype (CIMP).

I · Intervention 중재 / 시술

추출되지 않음

C · Comparison 대조 / 비교

추출되지 않음

O · Outcome 결과 / 결론

Conversely, the CIMP subtype was enriched in nonresponder patients with the shortest median overall survival and overall survival, along with a depleted immune microenvironment. A methylation-based probabilistic decision-making classification tool to predict the outcome of ICI treatment in patients with PM was developed.

Calabrò L, Caruso FP, Covre A, Noviello TMR, Lofiego MF, Tufano R, Ferraro L, Grisolia P, De Falco A, Lagano V, Sgambelluri F, Sabella G, Rossi G, Gibilisco G, Marzani F, Bello E, Simonetti E, D'Alonzo V, Caraglia M, Coral S, De Angelis A, Cerbone L, Delfanti S, Giannarelli D, Grosso F, Di Giacomo AM, Milione M, Mortarini R, Anichini A, Ceccarelli M, Maio M

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

📝 환자 설명용 한 줄

Pleural mesothelioma (PM) has a poor prognosis and standard therapy with immune checkpoint inhibitors (ICIs) CTLA-4 and PD-1 is still clinically unsatisfying.

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Calabrò L, Caruso FP, et al. (2026). Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study.. Nature genetics. https://doi.org/10.1038/s41588-026-02580-4

MLA Calabrò L, et al.. "Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study.." Nature genetics, 2026.

PMID 42045690

DOI 10.1038/s41588-026-02580-4

Abstract

Pleural mesothelioma (PM) has a poor prognosis and standard therapy with immune checkpoint inhibitors (ICIs) CTLA-4 and PD-1 is still clinically unsatisfying. No predictive biomarkers of ICI efficacy in PM are available yet. In the retrospective multicenter NIBIT-EPI-MESO study, multi-omics analysis of pre-ICI therapy tumor lesions from 91 patients with PM treated in earlier clinical trials or in daily practice identified four PM subsets with progressively increasing global DNA methylation profiles-demethylated, LOW, intermediate and CpG island methylator phenotype (CIMP). These methylation subsets predicted response and survival to ICI therapy. The LOW subset was enriched in responder patients, who had the longest median overall survival and the highest 3-year overall survival rate, and showed a T cell- and B cell-rich immune microenvironment. Conversely, the CIMP subtype was enriched in nonresponder patients with the shortest median overall survival and overall survival, along with a depleted immune microenvironment. A methylation-based probabilistic decision-making classification tool to predict the outcome of ICI treatment in patients with PM was developed.